Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Auxilium Co-promoting Testosterone Gel

By R&D Editors | May 21, 2012

MALVERN, Pa. (AP) – Drug developer Auxilium Pharmaceuticals Inc. improved its outlook for 2012 because of plans to start co-promoting its testosterone gel Testim in the U.S. this summer with British pharmaceutical giant GlaxoSmithKline plc.

Glaxo will get the right to jointly sell Testim with Auxilium in the United States through 2015, the companies said Monday. Auxilium CEO Adrian Adams said the deal was an effort to get Testim to more physicians.

Auxilium, based in Malvern, Pa., will remain responsible for making and supplying the gel, which is a testosterone replacement therapy for adult males. Testim brought in $58.7 million in revenue during Auxilium’s first quarter, nearly all of which came from U.S. sales. That made up 80 percent of Auxilium’s revenue for the quarter.

Glaxo said it expect to start selling the gel early in the third quarter. It said Testim will complement the cardiovascular, metabolic and urology products its representatives currently sell.

The British drugmaker’s payment will depend on how much the gel’s sales exceed a revenue forecast established by the companies. Auxilium also will make other payments to Glaxo that were not specified.

Auxilium now expects its 2012 net loss to range between $5 million and $10 million compared to a previous forecast calling for a loss of $5 million to $15 million. It raised its revenue guidance to a range of $293 million to $315 million from $283 million to $305 million.

Analysts surveyed by FactSet expect, on average, full year revenue of $299.1 million.

Date: May 21, 2012
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker: 83,543 and counting
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE